BioCentury
ARTICLE | Deals

Looking beyond lupus drug, Aurinia pads pipeline via pair of deals

Acquires Thunderbolt, partners with Riptide

August 17, 2021 10:38 PM UTC
Updated on Aug 20, 2021 at 11:08 PM UTC

Months after launching lupus nephritis drug Lupkynis, Aurinia has deepened its pipeline via deals to bring in two assets that could both be in the clinic within two years.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) said Tuesday it has gained BAFF/APRIL inhibitor AUR200 by acquiring Thunderbolt Pharma Inc., and has added MBR (CD206) modulator AUR300 via a licensing deal with Riptide Bioscience Inc...